Maya Sela
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maya Sela has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Abbas Rana
2 shared publications- Elijah Roberts
Office of Student Affairs Baylor College of Medicine Houston Texas USA
2 shared publications - Jose Ramirez
School of Medicine, Baylor College of Medicine, Houston, TX, USA
2 shared publications - Kiran Thirukonda
Office of Student Affairs Baylor College of Medicine Houston Texas USA
2 shared publications - Abbas Rana
Division of Abdominal Transplantation, Michael E. DeBakey Department of Surgery Baylor College of Medicine Houston Texas USA
1 shared publication - Arman Kavoussi1 shared publication
Latest Publications
- Open Access
- 7 August 2026
- Published by Elsevier in JTCVS Open
The Pediatric Heart Listing Mortality score: A score to estimate 12-month waitlist mortality risk in candidates awaiting heart transplant
- 7 August 2026
- Published by Elsevier in JTCVS Open
Open AccessThe Pediatric Heart Listing Mortality score: A score to estimate 12-month waitlist mortality risk in candidates awaiting heart transplant
- 8 July 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (11) , 5055-5061
Comparative Risk Profiles in the Surgical Management of Pediatric Sialorrhea
Objective: Sialorrhea commonly affects patients with neurodevelopmental disorders, resulting in aspiration risk and reduced quality of life. This study aims to compare the risk profiles for the surgical management of pediatric sialorrhea. Methods: A retrospective cohort study was performed using the American College of Surgeons' National Surgical Quality Improvement Program–Pediatric database (2012–2023) of patients undergoing surgery for sialorrhea in the operating room. 30‐day outcomes included medical complications, surgical complications, length of stay, unplanned reintubation, reoperation, readmission, and composite morbidity. Clinically relevant, significant variables on univariate analysis were retained for Firth's logistic regression. Results: Among 295 patients, 23% received botulinum injections (Bot‐Sal), 56% salivary duct ligation or re‐routing (SDL/R), 10% submandibular gland excision alone (SMGE), and 11% combined SMGE + SDL/R. Compared with Bot‐Sal, SDL/R was associated with lower odds of pulmonary complications (OR 0.18, 95% CI 0.06–0.56, p = 0.003), medical complications (OR 0.15, 95% CI 0.05–0.45, p = 0.001), and composite morbidity (OR 0.37, 95% CI 0.15–0.90, p = 0.027). Inpatient status (OR 5.04, 95% CI 1.87–13.62, p = 0.001) and CNS abnormalities (OR 2.70, 95% CI 1.07–6.79, p = 0.035) were independently associated with increased risk of pulmonary complications. There were no significant differences in surgical complications by procedure. Conclusion: Botulinum injections to the salivary glands in the operating room were associated with increased medical complications, specifically pulmonary, in this dataset, likely reflecting a combination of patient selection, clinical context, and procedural factors. Short‐term complication rates may help guide families regarding options for drooling procedures in the OR. Level of Evidence: 3
- 8 July 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (11) , 5055-5061
Comparative Risk Profiles in the Surgical Management of Pediatric Sialorrhea
Objective: Sialorrhea commonly affects patients with neurodevelopmental disorders, resulting in aspiration risk and reduced quality of life. This study aims to compare the risk profiles for the surgical management of pediatric sialorrhea. Methods: A retrospective cohort study was performed using the American College of Surgeons' National Surgical Quality Improvement Program–Pediatric database (2012–2023) of patients undergoing surgery for sialorrhea in the operating room. 30‐day outcomes included medical complications, surgical complications, length of stay, unplanned reintubation, reoperation, readmission, and composite morbidity. Clinically relevant, significant variables on univariate analysis were retained for Firth's logistic regression. Results: Among 295 patients, 23% received botulinum injections (Bot‐Sal), 56% salivary duct ligation or re‐routing (SDL/R), 10% submandibular gland excision alone (SMGE), and 11% combined SMGE + SDL/R. Compared with Bot‐Sal, SDL/R was associated with lower odds of pulmonary complications (OR 0.18, 95% CI 0.06–0.56, p = 0.003), medical complications (OR 0.15, 95% CI 0.05–0.45, p = 0.001), and composite morbidity (OR 0.37, 95% CI 0.15–0.90, p = 0.027). Inpatient status (OR 5.04, 95% CI 1.87–13.62, p = 0.001) and CNS abnormalities (OR 2.70, 95% CI 1.07–6.79, p = 0.035) were independently associated with increased risk of pulmonary complications. There were no significant differences in surgical complications by procedure. Conclusion: Botulinum injections to the salivary glands in the operating room were associated with increased medical complications, specifically pulmonary, in this dataset, likely reflecting a combination of patient selection, clinical context, and procedural factors. Short‐term complication rates may help guide families regarding options for drooling procedures in the OR. Level of Evidence: 3
- Open Access
- 6 May 2026
- Published by Wiley in Pediatric Pulmonology
- Vol. 61 (5) , e71656
Waiting List Survival Trends in Pediatric Lung Transplantation: A National Cohort Study
Background: Advancements in pediatric lung transplantation, including support devices, the Lung Allocation Score (LAS), and the subsequent Composite Allocation Score (CAS), have led to significant improvements in survival on the waiting list. Policy changes, like the removal of the Donation Service Area in 2017, aimed to further improve outcomes, but their impact in more recent years remains unclear. Our study examines recent waiting list survival trends and key factors affecting outcomes for pediatric lung transplant candidates. Methods: Pediatric patients ( n = 535) listed for lung transplantation in the OPTN Database were categorized into four eras based on year of listing: 2014–2017 ( n = 182), 2017–2020 ( n = 174), 2020–March 2023 ( n = 134), and March 2023 onward ( n = 45). Our primary outcome was death on the waiting list. Predictors of waitlist mortality were identified with multivariable logistic regression. Kaplan‐Meier curves with a log‐rank test were used to evaluate outcomes across eras. The Fine and Gray method was used to account for competing outcomes, including transplantation and removal from the waitlist due to clinical improvement. Results: Poor functional status, ventilation at time of listing, African American ethnicity, and listing in region 1 were associated with increased waitlist mortality. One‐year survival increased from 2014–2017 to 2020–2023 ( p < 0.05). When accounting for competing risks, Fine and Gray showed a declining incidence of waitlist mortality with each successive era. Conclusion: Waiting list survival for pediatric lung transplant candidates has improved since 2014, with notable progress in the 2020–2023 era. The reasons for these improvements are likely multifactorial, and further studies are needed to evaluate their impact.
- 6 May 2026
- Published by Wiley in Pediatric Pulmonology
- Vol. 61 (5) , e71656
Open AccessWaiting List Survival Trends in Pediatric Lung Transplantation: A National Cohort Study
Background: Advancements in pediatric lung transplantation, including support devices, the Lung Allocation Score (LAS), and the subsequent Composite Allocation Score (CAS), have led to significant improvements in survival on the waiting list. Policy changes, like the removal of the Donation Service Area in 2017, aimed to further improve outcomes, but their impact in more recent years remains unclear. Our study examines recent waiting list survival trends and key factors affecting outcomes for pediatric lung transplant candidates. Methods: Pediatric patients ( n = 535) listed for lung transplantation in the OPTN Database were categorized into four eras based on year of listing: 2014–2017 ( n = 182), 2017–2020 ( n = 174), 2020–March 2023 ( n = 134), and March 2023 onward ( n = 45). Our primary outcome was death on the waiting list. Predictors of waitlist mortality were identified with multivariable logistic regression. Kaplan‐Meier curves with a log‐rank test were used to evaluate outcomes across eras. The Fine and Gray method was used to account for competing outcomes, including transplantation and removal from the waitlist due to clinical improvement. Results: Poor functional status, ventilation at time of listing, African American ethnicity, and listing in region 1 were associated with increased waitlist mortality. One‐year survival increased from 2014–2017 to 2020–2023 ( p < 0.05). When accounting for competing risks, Fine and Gray showed a declining incidence of waitlist mortality with each successive era. Conclusion: Waiting list survival for pediatric lung transplant candidates has improved since 2014, with notable progress in the 2020–2023 era. The reasons for these improvements are likely multifactorial, and further studies are needed to evaluate their impact.
- 5 May 2026
- Published by Elsevier in Heart & Lung
- Vol. 79, 102833
Improved outcomes in adult lung transplantation: a two-decade national analysis
- 5 May 2026
- Published by Elsevier in Heart & Lung
- Vol. 79, 102833
Improved outcomes in adult lung transplantation: a two-decade national analysis